Physician profile
Beverly Ann Johnson
NPI 1255434742
$6,674.90
in general payments reported to CMS, 2019-2025
24 companies · $1,095 in 2025
The $1,095 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,676 · 2020: $445 · 2021: $436 · 2022: $231 · 2023: $594 · 2024: $2,197 · 2025: $1,095.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,438 · Consulting Fee: $1,350 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,438.37 |
| Consulting Fee | $1,350.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,840.30 | 2019-2025 | |
| Lilly USA, LLC | $580.59 | 2019-2024 | Olumiant, Taltz |
| Amgen INC. | $373.46 | 2020-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $373.44 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $347.49 | 2023-2025 | Zoryve |
| Ucb, INC. | $260.78 | 2019-2025 | Bimzelx |
| Incyte Corporation | $249.39 | 2024-2025 | Opzelura, Opzelura |
| Regeneron Healthcare Solutions, INC. | $220.83 | 2021-2025 | Dupixent |
| Galderma Laboratories, L.P. | $169.53 | 2019-2024 | Aklief, Oracea |
| Janssen Biotech, INC. | $140.21 | 2022-2025 | Tremfya |
| Almirall LLC | $134.91 | 2019 | |
| Johnson & Johnson Health Care Systems INC. | $130.58 | 2022 | |
| Dermavant Sciences, INC. | $119.55 | 2024 | Vtama |
| Janssen Scientific Affairs, LLC | $113.96 | 2019 | |
| Eli Lilly and Company | $99.00 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $94.18 | 2019-2020 | |
| Medline Industries LP | $85.88 | 2025 | |
| Sanofi-Aventis U.S. LLC | $72.00 | 2019 | |
| Pfizer INC. | $66.77 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $66.58 | 2019 | |
| Genzyme Corporation | $64.10 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $38.73 | 2025 | |
| Celgene Corporation | $16.70 | 2019 | |
| Viiv Healthcare Company | $15.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beverly Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.